Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025)
Innate Pharma (IPHA) reported Other Non-Current Liabilities of $386462.4 for Q4 2025, up 31.99% on a YoY basis from $292795.1 in Q4 2024, and down 25.78% quarter-over-quarter from $520701.5 in Q2 2025.
Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Innate Pharma has reported Other Non-Current Liabilities for 9 years, with the latest figure at $386462.4 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 31.99% year-over-year to $386462.4; the trailing twelve-month figure through Dec 2025 stood at $386462.4 (up 31.99% YoY), and the FY2025 full-year result was $386462.4, up 31.99% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $386462.4, down from $520701.5 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $648791.8 in Q4 2023, with the low at $202009.0 in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $373684.9 across 5 years, with a median of $304700.0 in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 221.17% — and 2024, when it plunged 54.87%.
- Innate Pharma's Other Non-Current Liabilities stood at $289424.7 in 2021, then slumped by 30.2% to $202009.0 in 2022, then surged by 221.17% to $648791.8 in 2023, then sank by 54.87% to $292795.1 in 2024, then soared by 31.99% to $386462.4 in 2025.
- The last three Other Non-Current Liabilities figures came in at $386462.4 (Q4 2025), $520701.5 (Q2 2025), and $292795.1 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 386,462.45 |
| Jun 30, 2025 | 520,701.46 |
| Dec 31, 2024 | 292,795.14 |
| Jun 30, 2024 | 316,604.95 |
| Dec 31, 2023 | 648,791.77 |
| Jun 30, 2023 | 537,928.65 |
| Dec 31, 2022 | 202,008.98 |
| Jun 30, 2022 | 269,965.34 |
| Dec 31, 2021 | 289,424.65 |
| Jun 30, 2021 | 272,165.34 |
| Dec 31, 2020 | 263,496.06 |
| Jun 30, 2020 | 288,582.55 |
| Dec 31, 2019 | 157,178.05 |
| Dec 31, 2018 | 43,373.06 |
| Dec 31, 2017 | 1.19 Mn |